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2014, accepted Janhe recently commercially available subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) uses a completely
subcutaneous electrode conﬁguration to treat potentially lethal ventricular tachyarrhythmia. Clinical trials have
proven its effectiveness in detecting and treating ventricular ﬁbrillation and tachycardia. The S-ICD offers
the advantage of eliminating the need for intravenous and intracardiac leads and their associated risks
and shortcomings. However, its major disadvantage is its inability to provide bradycardia rate support and
antitachycardia pacing to terminate ventricular tachycardia. This paper discusses the S-ICD clinical trials and
advantages and disadvantages of this novel technology to help the physician identify its role and select candidate
patients who will beneﬁt from this device. (J Am Coll Cardiol 2014;63:1473–9) ª 2014 by the American College
of Cardiology FoundationSudden cardiac death (SCD) affects 350,000 individuals
each year, accounting for half of all cardiac deaths in devel-
oped countries (1). The introduction of the implantable
cardioverter-deﬁbrillator (ICD) into clinical practice over
the past 25 years has provided life-saving therapy as primary
and secondary prevention of SCD to more than 1 million
patients worldwide (2). ICD technology evolved from devices
that delivered therapy through epicardial patch electrodes
introduced by thoracotomy to those using transvenous leads
advanced to the right ventricle for detection and treatment
of tachyarrhythmia and to provide bradycardia-pacing sup-
port. The transvenous ICD (T-ICD) reduced the morbidity
and risk associated with thoracotomy implants. However,
use of transvenous leads involves potential complications
including hemopericardium, hemothorax, pneumothorax,
lead dislodgement, lead malfunction, device-related infec-
tion, and venous occlusion (3).
Lead malfunction caused by conductor failure or insu-
lation breach occurs in up to 40% of indwelling transvenous
leads at 8 years after implantation (4). Failure occurs more
commonly in active young patients or in patients with longer
life expectancy who expose the leads to greater cumulative
physical stress. Longer-living ICD patients may also un-
dergo several generator exchanges, each with an associated
risk of pocket infection reaching up to 3%. Because lead
malfunction may necessitate, and device infection usually
requires, extraction of the lead, use of transvenous pacingof Medicine, University of Leeds, Leeds, United Kingdom; and the
ophysiology, Division of Cardiology, Department of Medicine,
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ived November 15, 2013; revised manuscript received January 9,
uary 14, 2014.and deﬁbrillating leads introduces the potential risk of
extraction-associated morbidity and mortality (5) to patients
with chronically present transvenous leads.
Initial attempts to avoid the use of an endovascular de-
ﬁbrillating system in pediatric patients, patients with difﬁ-
cult or absent venous access, and patients at high risk of
bacteremia (i.e., patients with chronic indwelling catheters)
involved the use of ICD systems with nontransvenous
deﬁbrillating components (6–8). However, those early devi-
ces still relied on epicardial or transvenous pacing systems
for ventricular sensing for arrhythmia detection. The need
to completely avoid venous access issues, endovascular me-
chanical stress producing lead malfunction, and extraction-
associated risks led to the development of the entirely
subcutaneous ICD (S-ICD). Its unique design avoids en-
dovascular leads, thus eliminating many of the complications
associated with the traditional T-ICD. The novel device,
developed and tested over the past decade, gained approval
as accepted therapy for detection and termination of ven-
tricular arrhythmias. The European Union approved its use
in 2009; the U.S. Food and Drug Administration approved
it in 2012. Worldwide, implants over the past 2 years exceed
2,000 units.S-ICD System
The S-ICD system (model SQ-RX 1010, Cameron Health,
Inc., San Clemente, California) includes a dedicated external
programmer, a subcutaneous pulse generator enclosed in a
titanium case, and a single subcutaneous electrode contain-
ing both sensing and deﬁbrillating components. The lead is
composed of a proximal and a distal sensing electrode
positioned adjacent to either end of a 3-inch deﬁbrillation
coil electrode. The recommended position for the pulse
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1474generator involves a subcutane-
ous pocket created over the ﬁfth
intercostal space between the
mid and anterior axillary lines.
The subcutaneous lead should lie
parallel to the left side of the
sternum, with its upper pole an-
chored at the level of the sternal
notch and the lower electrode
anchored just below the level of
the xiphoid process. The elec-
trode then makes a right-angle
turn laterally to enter the pulse
generator pocket (Figs. 1Aand1B).
Implantation of the device relies
exclusively on anatomical land-marks,with the option to conﬁrmdeﬁbrillating electrodeposition
by ﬂuoroscopy.hest Radiographs of a Patient With
d as arrows of different colors: the primary
ctrode and the ICD scan; the secondary vector
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osteroanterior; S-ICD ¼ subcutaneous
.The S-ICD system detects changes in ventricular rate
by using modiﬁed subsurface electrocardiography through
either a primary, secondary, or alternate vector (Fig. 1A).
The device uses proprietary algorithms to automatically
determine the optimal sensing vector based on an R- to T-
wave ratio that avoids double QRS counting or T-wave
oversensing. It measures the heart rate as the rolling average
of 4 consecutive sensed intervals, recognizing ventricular
ﬁbrillation (VF) when 18 of 24 consecutive sensed events
exceed a pre-determined nonprogrammable detection zone
limit. The device then charges its capacitors to deliver a
biphasic-waveform deﬁbrillating pulse of up to 80 J. The
S-ICD can provide post-shock bradycardia ventricular pac-
ing support for 30 s (Fig. 2).
The current pulse generator weighs 145 g and has a
volume of 69 ml (Fig. 3). The manufacturer estimates
longevity of the battery to be 5 years (9).
S-ICD Clinical Trials
Bardy et al. (10) summarized the early clinical testing
experience with the S-ICD, from acute studies to test the
optimal sensing and deﬁbrillation conﬁguration, to the ini-
tial long-term follow-up of fully functional devices. The
ﬁrst acute evaluation identiﬁed the optimal deﬁbrillation
conﬁguration as a combination of parasternal electrode and
left lateral thoracic pulse generator. A comparison of the
S-ICD deﬁbrillation system with a T-ICD in 2004 (n ¼ 49)
found that the S-ICD equally terminated induced VF,
although at a higher deﬁbrillation threshold (DFT) than
that of the T-ICD (36.6  19.8 J vs. 11.1  8.5 J,
respectively). A pilot study in 2008 (n ¼ 6) showed that the
implanted S-ICD effectively detected and terminated 2
consecutive episodes of induced VF acutely with no inap-
propriate shocks or device complications during a 488  2
day follow-up. An expanded evaluation (n ¼ 55) showed
that the device terminated induced VF at implant with 98%
efﬁcacy but also detected and terminated 12 episodes of
spontaneous ventricular tachycardia (VT)/VF in 3 patients.
However, 3 patients experienced inappropriate sensing due
to muscle noise, 6 patients experienced lead migration/
dislodgement, and 2 patients developed device infection.
Dabiri Abkenari et al. (11) reported a single-center Eu-
ropean experience (n ¼ 31) with the S-ICD in which the
device detected and terminated 100% of induced VF epi-
sodes. Additionally, 4 patients with spontaneous VF/VT
received successful therapy during follow-up; 5 patients
received inappropriate shocks; and 2 patients experienced
lead migration that required operative repositioning.
A multicenter trial from the Netherlands (n ¼ 118)
conducted between 2008 and 2011 reported a 177–patient-
year follow-up (12). The S-ICD successfully detected
9 episodes of spontaneous VT and 36 episodes of sponta-
neous VF in 8 patients. It successfully treated 98% of these
episodes (1 VT episode accelerated into VF and terminated
before delivery of a second shock). However, 13% of patients
Figure 2 Appropriate ICD Shock
An electrogram from a patient with an S-ICD who received a shock for fast ventricular tachycardia (lightening symbol) with restoration of sinus rhythm with premature beats.
S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator.
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1475experienced inappropriate shocks for multiple reasons: 3
developed lead migration, creating the need to develop a
sleeve that anchored the lead as it turned laterally at the sub-
xiphoid level; 2 patients developed skin erosion over the
device pocket; and infection occurred in 7 patients, requiring
removal of the device. The highest rate of inappropriate
shocks and device-related complications occurred in the ﬁrstFigure 3 S-ICD Size
The S-ICD (middle) with 2 different T-ICDs from 2 different device manufacturers.
Note the larger size of the S-ICD. S-ICD ¼ subcutaneous implantable cardioverter-
deﬁbrillator; T-ICD ¼ transvenous implantable cardioverter-deﬁbrillator.15 implanted devices in each of the centers, suggesting the
presence of a learning curve associated with this new tech-
nology (12).
The early UK S-ICD experience (n ¼ 111) included a
group mean age of 33 years (range: 10 to 87 years) with
primary cardiac electrical heart disease (43%), hypertrophic
cardiomyopathy (20%), and ischemic cardiomyopathy
(14%) (13). The device detected and treated all induced
episodes and all 10 spontaneous episodes of VF and 14 of
VT. Complications included device-related infection or
skin erosion requiring reoperation in 17% of patients. A
total of 15% of patients received inappropriate shocks;
younger patients experienced a higher rate of inappropriate
shocks because of T-wave oversensing. Another multi-
center evaluation of the S-ICD that included a mixed
pediatric and adult population also demonstrated inap-
propriate shocks due to T-wave oversensing in younger
patients (5).
The largest multicenter clinical evaluation of the safety
and efﬁcacy of the S-ICD enrolled 330 individuals with
established indications for an ICD (14). Nine patients
withdrew before device implantation, and 17 patients did
not undergo DFT testing; 304 enrolled subjects under-
went successful implantation and DFT testing. The S-ICD
terminated all induced VF episodes. Twenty-one subjects
experienced 119 episodes of spontaneous VT/VF, 38 as
isolated events and 81 as part of a VT storm. The device
successfully terminated 37 of 38 isolated episodes; 1 VT
terminated as the device was charging to deliver a second
shock. The S-ICD successfully treated all VT storm events.
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1476Forty-one patients (13.1%) received an inappropriate shock;
the cause was treatment for supraventricular tachycardia in
16 patients and oversensing in the other 25. Eighteen sub-
jects developed pocket infections (5.6%); 4 required device
explantation, and 1 required pocket revision (1.56% rate of
intervention for infection).
A recently reported multicenter case control study (n ¼
69) compared deﬁbrillation efﬁcacy in patients receiving an
S-ICD with an age- and sex-matched cohort receiving a
T-ICD (15). The S-ICD ﬁrst shock efﬁcacy in terminating
induced VF using a 15-J safety margin was 89.5%, compared
to 90.8% with the T-ICD, at a 10-J safety margin (p ¼ 0.8).
The success rate with the S-ICD increased to 95.5% after
a second shock by using reverse electrode polarity. Another
small study (n ¼ 40) reported a ﬁrst shock efﬁcacy of 58%
with an overall shock efﬁcacy of 96% (for induced and
spontaneous VF/VT) after additional shocks (16).
Discussion
Development of the S-ICD represents a quantum step in
the evolution of ICD technology to prevent SCD. Data
from the S-ICD clinical trials support its efﬁcacy and
safety in detecting and terminating VT. Although the ﬁrst-
generation device experience included adverse events such as
sensing issues that led to inappropriate shocks, lead migra-
tion, and device infection, their frequency appears to beFigure 4 Inappropriate ICD Shock
An inappropriate shock delivered by the S-ICD as a result of T-wave oversensing during swithin the bounds of clinical experience with T-ICD, and
the preponderance of device infection and lead migration
early in a center’s experience is consistent with a learning
curve. The advantages of a nontransvenous ICD system
include elimination of complications related to venous ac-
cess, no physical stress on leads associated with cardiac
motion, less morbidity associated with device extraction, and
a potential reduction in endovascular infection risk to pa-
tients with dialysis access or endovascular prostheses. The
limitations of the current S-ICD include its inability to
provide antitachycardia pacing for VT, limited bradycardia
pacing support, relatively large size and bulk of the pulse
generator, and absence of endovascular monitoring capa-
bilities for collateral data gathering such as impedance
monitoring for chronic heart failure.
One estimate of potential candidates for the S-ICD
might include every patient indicated for primary SCD
prevention without a pacing indication. However, the lim-
itations of the current system and the relative paucity of
data on long-term performance compared with that of the
T-ICD might temper that view (2). The S-ICD appears
to be an attractive alternative in relatively young patients
(i.e., age <40 years), those at high-risk for bacteremia (due
to indwelling catheters/hardware or immune-compromised
states), and patients lacking venous access. Without the
use of transvenous leads, most major complications associ-
ated with their use are avoided. Given that the duration ofinus tachycardia. S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator.
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1477implanted leads greatly inﬂuences the probability of mal-
function, the S-ICD presents an attractive alternative in
younger patients with greater longevity, such as those with
hypertrophic cardiomyopathy and inherited ion channel
abnormalities. The potential advantage of the S-ICD in the
young is tempered to some degree by the higher rate of
inappropriate shocks seen in this group of patients. No study
has prospectively addressed the use of ICD therapy as pri-
mary prevention of SCD in the dialysis population; all the
clinical trials actively excluded enrolling dialysis patients.
The S-ICD clinical evaluation protocols also excluded en-
rollment of patients with chronic kidney disease requiring
dialysis; yet it may provide a safer approach in this group of
patients with a greater risk for infection due to access
catheters, limited venous access due to scarring, and greater
lead extraction-related complications due to increased cal-
ciﬁcation around implanted leads. Use of the S-ICD should
be avoided in patients with either known monomorphic
VT or with conditions (sarcoidosis or arrhythmogenic right
ventricular cardiomyopathy) likely to result in VT amenable
to antitachycardia pacing (17).
The S-ICD system delivers energy to the heart in a
more homogenously distributed pattern than the endocardial
shock delivered by the T-ICD (18). The uneven distribution
of energy across the myocardium after an endocardial shock
can produce voltage gradients and electroporation resulting
in myocardial stunning and damage (19,20). Endocardial
shocks produce signiﬁcant troponin release; shocks delivered
from subcutaneous electrodes do not (21,22). Myocardial
injury and stunning associated with ICD discharge might
explain the increased mortality seen in heart failure patients
receiving multiple shocks (23,24). Whether the lack of sig-
niﬁcant troponin release after a subcutaneous shock consti-
tutes an advantage the S-ICD and whether it translates into
a survival beneﬁt remain to be determined.
The use of a subcutaneous sensing electrode with the
S-ICD may theoretically increase the risk of oversensing
noise or myopotential signals and undersensing low-
amplitude cardiac signals during VF. The START (Subcu-
taneous vs. Transvenous Arrhythmia Recognition Testing)
trial compared arrhythmia detection of 3 commercially
available T-ICD lead systems versus the S-ICD electrode
(25). All devices excelled in detecting ventricular tachyar-
rhythmia (100%); however, the S-ICD demonstrated greater
speciﬁcity in discriminating supraventricular from ventricular
tachycardia (98% S-ICD vs. 76.7% single-chamber T-ICD
vs. 68% dual-chamber T-ICD).
The rate of inappropriate shocks observed in the S-ICD
trials ranged from 5% to 25% (Table 1), a frequency similar
to the observed rate reported in earlier trials of the T-ICD
(26). However, more recent T-ICD trials show that newer
algorithms reduce the rate of inappropriate shocks to less
than 5% (24), suggesting an advantage of T-ICDs over the
current S-ICD. Ideally, greater user programming experi-
ence and improvements in S-ICD technology may reduce
the rate of inappropriate shocks (14).
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1478An increased ventricular rate during atrial arrhythmia
constitutes the major cause of inappropriate shocks delivered
by T-ICD systems. However, oversensing T waves or
myopotential signals produces most inappropriate S-ICD
shocks (Fig. 4) (13,26,27). Inappropriate shocks occur more
frequently in younger, physically active patients, the group
most likely to beneﬁt from the features of the S-ICD system
(5,13). The addition of a second tachycardia zone to S-ICD
programming may signiﬁcantly reduce the rate of inappro-
priate shocks (14).
The rate of infection with S-ICD systems ranges up to
10% of implants (13). The larger studies to date reported
similar rates of infection (5.9% [12] and 5.6% [27]). One
study advocated the adequacy of conservative treatment with
a low need for intervention (1.56%) (27); yet, another study
reported a greater need for surgical intervention or device
removal (13). The rate of pocket infection with the S-ICD
exceeds that with the T-ICD. The 3 incisions required for
S-ICD implantation provide a greater probability for bac-
terial entry. Also, the increased bulk of the S-ICD may exert
more pressure on the skin and increase the risk of tissue
necrosis and erosion. The infection rate may decrease with
more operator experience, introduction of smaller pulse
generators, and use of a 2-incision technique for system
implantation (28).
Other limitations of the S-ICD typify the ﬁrst-generation
nature of the current device: lack of continuous demand
and antitachycardia pacing contraindicates the use of the
S-ICD in patients with sinus node dysfunction, atrioven-
tricular block, or an indication for cardiac resynchronization.
Because 80% of spontaneous VT episodes respond to pain-
less antitachycardia pacing (17), patients with a history of
VT beneﬁt more from a T-ICD (23,29). The longevity of
the S-ICD battery is estimated at 5 years compared with
the most recently introduced single-lead T-ICD that may
exceed 10 years. In addition, the S-ICD system lacks remote
monitoring capability, a feature that improves patient out-
comes and simpliﬁes follow-up (30,31).
Conclusions
The clinical experience from the introduction of the S-ICD
system underscores its role as a reliable alternative for pre-
venting SCD. The exclusive use of a subcutaneous lead for
sensing and deﬁbrillation represents the greatest advantage
of this novel technology; the S-ICD eliminates the draw-
backs associated with endovascular electrodes. However, the
lack of demand bradycardia or anti-tachycardia pacing
limits its utility in patients with conduction system disease
or pace-terminable VT. The ﬁrst-generation device raises
concerns about an increased risk of pocket infection, battery
longevity, and inappropriate shocks compared with the
newest T-ICD systems. No study to date directly compared
the T-ICD and the S-ICD in patients indicated for ICD
therapy as primary prevention of SCD. The clinical expe-
rience does suggest that its use be considered in relativelyyounger patients (i.e., age <40 years), those at increased risk
for bacteremia, patients with indwelling intravascular
hardware at risk for endovascular infection, or in patients
with compromised venous access. As seen with other early
examples of evolutionary technology, improvements in
design and manufacture will improve upon some of the
drawbacks of a ﬁrst-generation device.
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